Invitation to tender for ctDNA next generation sequencing assay at St Mary’s Hospital for non-small cell lung cancer detection, with a 5-year initial term and potential for a 2-year extension.
ctDNA Testing. Invitation to tender for Circulating tumour DNA (ctDNA) next generation sequencing (NGS) assay.
Manchester University NHS Foundation Trust (MFT) has a requirement for ctDNA testing of non-small cell lung cancer, at St Mary’s Hospital, Genomic Medicine. MFT are requiring a ctDNA Next Generation Sequencing (NGS) assay which can detect non-small cell lung cancer. MFT has been indicated by NHS England (NHSE) that it will act as a centre to commission ctDNA testing following an application to NHSE. MFT are looking to establish a high throughput service for the North West Genomic Laboratory Hub (GLH), working on behalf of the national network.
The contract will be a 5 year initial term with an option to extend for an additional 2 years in 1 year instalments. The first year of the contract will be a bridging service to the awarded supplier. The testing will then be provided within St Mary's Hospital, 5th Floor for the remaining duration of the contract.